EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The evolving role of perioperative systemic therapy in bladder cancer

Saad O Atiq iD, Jonathan F Anker, Eric J Miller, Alexander B Karol iD, Reza Mehrazin, John P Sfakianos, Matthew D Galsky

Cancer · 01.11.2026 · 132 (21)

DOI: 10.1002/cncr.70629 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer, online erschienen am 30.10.2026. Verfasst von Saad O Atiq und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 84 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The treatment landscape for muscle‐invasive bladder cancer has recently been transformed by two key phase 3 studies of perioperative enfortumab vedotin plus pembrolizumab. These trials have demonstrated significant improvements in event‐free survival and overall survival compared with the previous standards of care, marking a new era in the management of patients with muscle‐invasive bladder cancer that is no longer defined by cisplatin eligibility. The focus is now shifting toward the identification of additional novel therapeutic targets for further improved outcomes as well as response‐guided treatment pathways seeking to optimize both cancer control and survivorship.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansAntibodies, Monoclonal, HumanizedPerioperative CareAntibodies, MonoclonalCystectomyClinical Trials, Phase III as Topic

Stichwörter der Autor:innen

antibody drug conjugatesbladder cancercystectomyimmune checkpoint inhibitorsimmunotherapyperioperative therapyurothelial carcinoma

Substanzen

Antibodies, Monoclonal, Humanizedpembrolizumabenfortumab vedotinAntibodies, Monoclonal

Autor:innen und Institutionen

  • Division of Hematology/Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

ORCID-Profile: Saad O Atiq, Alexander B Karol

Zitieren

APA

Atiq, S. O., Anker, J. F., Miller, E. J., Karol, A. B., Mehrazin, R., Sfakianos, J. P., & Galsky, M. D. (2026). The evolving role of perioperative systemic therapy in bladder cancer. Cancer, 132(21). https://doi.org/10.1002/cncr.70629

Vancouver

Atiq SO, Anker JF, Miller EJ, Karol AB, Mehrazin R, Sfakianos JP, et al. The evolving role of perioperative systemic therapy in bladder cancer. Cancer. 2026;132(21). doi:10.1002/cncr.70629

BibTeX
@article{Atiq2026,
  author = {Atiq, Saad O and Anker, Jonathan F and Miller, Eric J and Karol, Alexander B and Mehrazin, Reza and Sfakianos, John P and Galsky, Matthew D},
  title = {The evolving role of perioperative systemic therapy in bladder cancer},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {21},
  doi = {10.1002/cncr.70629}
}
Kostenlos starten →